Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

The Yahoo Finance headline says Ligand Pharmaceuticals is pursuing a “massive” XOMA acquisition that would double its royalty book. No deal value, financing structure, expected closing date, acquired assets, or management commentary is included in the available feed, and the primary-report record is feed-only.

Ligand’s latest enrichment is an older fiscal-year snapshot for the year ended December 31, 2025: revenue was $268.1 million, up 60.4% year over year, with diluted EPS of $6.13 and a 46.4% net margin. Those figures establish a growing royalty-based business, but they do not show the pro forma effect of XOMA or distinguish the acquisition’s contribution from existing portfolio performance.

The direct link is between Ligand’s royalty revenue model and XOMA’s royalty assets: if the transaction closes on acceptable terms, Ligand would gain a larger stream of partnered-product economics; if it requires substantial financing or brings weaker-than-expected assets, the enlarged book could add leverage or dilute returns. The headline does not identify the individual contracts, products, or counterparties involved.

The key uncertainty is the absence of primary evidence and transaction specifics. “Doubles the royalty book” is a material claim, but the available record does not establish how the book is being measured, whether the acquisition is signed or merely proposed, or what consideration Ligand would pay.

The next decisive evidence would be a definitive merger announcement, SEC filing, or closing disclosure that gives the purchase price, funding mix, expected royalty contribution, and timing. No dated event is supplied in the available material, so the trade read remains non-convictional.